Opko and entera bio

Well I for one can barely contain my excitement that Opko and its partner "have completed a proof of concept single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment."

It takes a lot of balls to shake up the market with such an announcement. The broad implications are too many to list.

After we finish the next phases, which include validation of the rodent results with additional tests on:
Porcupines
Squirrels
Agouti
Beavers
Gophers
Gerbils
Hamsters
Chinchilla
and Moles

we'll then do a double blind confirmatory study on albino mice

This battery of trials is expected to take 5 years, at which point we hope to conclude the proof of concept portion of the trials.

We will then exhume Phil Frost's body, prop him up at a seance table, consult our ouija board and Phil's spirit will attempt to contact Harry Houdini. If successful in reaching Harry, Phil's ghost will remove the magician's straight jacket, from his last, unfortunately fatal magic trick, and instruct Harry to travel to the Netherworld to contact Phil's ol' lunch buddy, The Almighty Himself, and ask whether Opko should move the GLP-2 asset from rodent to clinic.

Opko being Opko.....serving the unmet needs....of the dead, and undead.

At least Entera puts out press releases

Okay, it will probably take longer to bear fruit than Modex's efforts. Probably take longer than either Frost or I will be around to realize any benefit.



ENTX finished up 4.95% on 1,431,235 shares vs the 10day average of 75,386. Most of which came when the news broke. We'll see what tomorrow bring for the stock, but to rack up such a hefty increase in volume, it looks like there are people paying attention.

I think Bourla may have gone off the deep end. Pfizer seems to now be infected with Opko CEO syndrome. News of a $3+ billion windfall coming PFE's way through the sale of some Haleon shares has been met with.....a 'meh' by investors. Stock barely noticed. 

If the Pfizer BOD is worth what they're being paid, they've had a few discussions with Bourla by now, and have the corporate equivalent of an ankle bracelet on him. He's on thin ice, or at least should be. if he falls through, stock will likely move higher, and that 6% dividend yield will go down.